February 01, 2015 9:38 PM ET

Pharmaceuticals

Company Overview of Teva Pharmaceuticals USA, Inc.

Company Overview

Teva Pharmaceuticals USA, Inc. develops, manufactures, and supplies generic prescription medications in the United States. It offers various therapeutic medications in the areas of cardiovascular, anti-infective, central nervous system, anti-inflammatory, oncolytic, anti-diabetic, analgesic, dermatologic, respiratory, and women's health, as well as provides oncology products and latex-free products. The company offers its products in various dosage forms, such as tablets, capsules, injectables, creams, ointments, inhalants, solutions, and suspensions. It serves patients through distributors. Teva Pharmaceuticals USA, Inc. was formerly known as Lemmon Pharmacal Company and changed its name to...

1090 Horsham Road

North Wales, PA 19454

United States

Founded in 1945

Phone:

215-591-3000

Fax:

215-591-8600

Key Executives for Teva Pharmaceuticals USA, Inc.

Chief Executive Officer of Teva North America and President of Teva North America
Age: 66
Vice President of Government Affairs
Vice President of Government Affairs
Vice President of Government Affairs
Vice President of Government Affairs
Compensation as of Fiscal Year 2014.

Teva Pharmaceuticals USA, Inc. Key Developments

Teva Pharmaceuticals USA, Inc. Announces Layoffs At New York Plant

Teva Pharmaceuticals USA Inc. announced another round of layoffs at its Pomona, New York plant -- just a two-hour drive south of Albany. Teva will lay off four employees before the end of March 2015, according to documents filed with the New York state Department of Labor. The company cited economic troubles as the reason for dislocation.

Teva Pharmaceuticals USA, Inc. Settles Patent Litigation with Pfizer on Celebrex(R)

Teva Pharmaceuticals USA, Inc. has entered into a settlement with Pfizer related to Teva's generic version of Celebrex(R) (celecoxib) 50, 100, 200 and 400 mg capsules in the United States. Under the terms of the settlement, Teva may launch its generic versions in December, 2014, or earlier under certain circumstances. Teva has received tentative approval from the U.S. Food and Drug Administration (FDA) for all strengths and believes that it is first-to-file on at least the 100, 200 and 400 mg capsules. Sales of Celebrex(R) were $2.2 billion in the U.S. according to IMS data as of December, 2013.

Teva Pharmaceuticals USA, Inc. Presents at Latin America & Caribbean Life Sciences Conference, Mar-28-2014 10:45 AM

Teva Pharmaceuticals USA, Inc. Presents at Latin America & Caribbean Life Sciences Conference, Mar-28-2014 10:45 AM. Venue: Graham Center Ballroom, FIU-Maidique Campus, Miami, Florida, United States. Speakers: Michelle Cuccia, Vice President for Commercial Operations, Latin America.

Similar Private Companies By Industry

Company Name Region
Alevium Pharmaceuticals Inc. United States
Wyeth Laboratories Inc. United States
Silvergate Pharmaceuticals, Inc. United States
Macoven Pharmaceuticals, LLC United States
Alfama, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Teva Pharmaceuticals USA, Inc., please visit www.tevagenerics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.